Summary
Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) isolated from Pteris Semipinnata L is known to inhibit certain tumor cells in vitro. The information on the in vivo effect of 5F is limited and its effect on hepatocellular carcinoma (HCC) is unknown. In this study, the anti-tumor effect of 5F was investigated in a diethylnitrosamine (DEN)-induced mouse HCC model. In addition to therapeutic effect, the potential side effect was monitored. A panel of cultured HCC cells was used to confirm the in vivo data and explore the responsible molecular pathway. The result showed that 5F significantly inhibited the DEN-induced HCC tumors by reducing the number of tumor foci and the volume of tumors. Furthermore, 5F induced the death of cultured HCC cells in dose- and time-dependent manners. The cell death was confirmed to be apoptotic by in vivo and in vitro TUNEL assays. 5F inhibited NF-kB by stabilizing its inhibitor IkBα, reducing the nuclear p65 and inhibiting NF-kB activity. Subsequently it affected the NF-kB downstream molecules with a decrease in anti-apoptotic Bcl-2 and increase in pro-apoptotic Bax and Bak. During the whole period of the experiment, mice receiving 5F appeared to be healthy, though they suffered from a mild degree of hair loss. 5F did not damage liver and renal functions. In conclusion, 5F is effective against HCC with minimal side effects. It induces apoptosis in HCC cells via inhibiting NF-kB, leading to the decrease of Bcl-2 but the increase of Bax and Bak.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers affecting millions of individuals worldwide. Surgical treatments of HCC, including resection, transplantation, and local ablation, are considered as a potentially curative therapy. However, about 80–90% of patients are not eligible for such treatments at diagnosis [1]. The treatment options for these patients are mainly palliative, such as transarterial chemoembolization, intra-arterial or systemic chemotherapy, radiotherapy and immunotherapy, and the 5-year relative survival rate for them is only 7% [2]. Moreover, patients who have received surgical treatments are also at risk of recurrence at a rate of approximately 50% at 3 years [2]. The above situations highlight the urgent need for new therapeutic approaches for this malignancy.
Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid is the fifth fraction isolated from Pteris Semipinnata L. For simplicity, this compound is termed as 5F. 5F is able to kill various human cancer cells including thyroid cells, nasopharyngeal carcinoma cells, gastric cancer cells, and colorectal cancer cells in vitro [3–9]. Experiments have shown that 5F induces apoptosis of human cancer cells in a concentration- and time-dependent manner [6–8]. Studies have suggesting that cell death induced by 5F is through a mitochondrial-mediated pathway. However, the information of in vivo anti-tumor effect of 5F is limited, and its potential side-effect is basically unknown. The anti-HCC property of 5F has also not yet been investigated. This study therefore was to determine the tumorcidal effect of 5F on in vitro cultured HCC cells and an in vivo HCC mouse model.
Materials and methods
Chemicals and reagents
5F was prepared as the previous description [3, 5]. All antibodies used were obtained from Santa Cruz (Santa Cruz, CA). Other reagents, if not specifically indicated, were purchased from Sigma (St Louis, MO).
Animal model and treatment, and tumor calculation
Infant C3H/HeJ mice (Bar Harbor, ME) at 4–6 days old were randomly divided into 8 groups detailed in Table 1 and each group contained 10 mice. The liver carcinogen diethylnitrosamine (DEN) was used to induce HCC in the mice according to the published procedure [10, 11]. After the administration of DEN, the tumor was allowed to develop for 17 weeks. 5F treatment started at the first day of the 17th week. 5F dissolved in saline was intraperitoneally injected at designated concentrations (Table 1), and given for 5 consecutive days per week. Three types of controls were set up. Mice received DEN only were the positive tumor control (Group 4). Mice without DEN induction but treated with 5F were the 5F-only control (Groups 5–7). Mice received saline only were the vehicle control (Group 8). The treatment lasted for 12 weeks. The mice were maintained under standardized conditions in the Research Animal Resources facility of our institute according to the ethical animal guideline. The weight of individual mouse was monitored bi-weekly. The blood was drawn by direct venal puncture at the posterior vena cava. Livers of all mice were dissected and weighted after the completion of treatments. Four sections taken from the different parts of the liver were used for hematoxylin and eosin (H&E) staining. The number of tumors was counted under the light microscopy. The volume of each visible tumor was calculated by a formula: volume = πd/2 [12, 13], where d = diameter of the tumor, and the total volume of the tumors in each individual mouse was accordingly determined.
Biochemical parameters related to liver and renal functions
Mouse blood was collected and serum was isolated for testing aspartate aminotransferrase (AST), alanine aminotransferrase (ALT), serum creatinine (CRE), and blood urea nitrogen (BUN) to determine the side-effect of 5F. The former two parameters were used to test the liver function, and the latter two the renal function. The assay kits for the above 4 parameters were provided by King Hawk Pharmaceutics (Beijing, China) and performed according to the manufacturer’s instructions. The reference ranges for these parameters in mice are: AST < 37U/L, ALT < 40U/L, CRE < 106 μmol/L, BUN range of 1.8–7.1 mmol/L and panic concentration >35.7 mmol/L [14].
Immunohistochemistry
Immunohistochemical staining of proliferating cell nuclear antigen (PCNA), Bcl-2, Bcl-xL, Bax, Bak, Bid, p65, and I-kBα was performed and the positive staining was graded as described previously [6, 15]. Briefly, samples with less than 10% of positive cells in 20 random high-power fields was scored as 1; samples with 10%–30% of positive cells were positive as 2; samples with 30%–50% of positive cells were positive as 3 and samples with more than 50% of positive cells were positive as 4.
Cell cultures
The human liver cell lines SK-Hep-1, Huh-7, PLC/PRF/5, HepG2 and Hep3B were cultured as described previously [16, 17].
Cell viability and apoptosis
Cell viability was measured by MTT assay [16, 17]. Apoptosis of cultured cells was determined by APO-BRDU Flow cytometry kit for apoptosis (Phoenix Flow Systems, San Diego, CA) [3, 18]. The in vivo apoptotic cells was assessed by In Situ Cell Death Detection Kit (TUNEL assay) (Roche, Penzberg, Germany) and performed according to the instructions of the manufacturers.
Western blot
Western blot was carried out as described previously [6, 9].
NF-kB p65 activity
The nuclear extract was isolated for the measurement of p65 activity, which was determined with an NF-κB (p65) Transcription Factor Assay ELISA kit from Cayman Chemical (Ann Arbor, MI) and performed according to the manufacturer’s instruction.
Statistical analysis
Data were expressed as mean±SD. Statistical differences between groups were examined using the One-Way ANOVA and student’s t test. There was statistically significant difference when P < 0.05.
Results
Effects of 5F on the number and volume of tumors
The in vivo effect of 5F was examined in a DEN-induced mouse HCC model and three different doses of 5F were given (Table 1). It was found that 5F at 24 and 48 mg/kg could significantly reduce the number of tumors induced by DEN, compared with mice without 5F treatment (Fig. 1a, b). Similar effects were observed on the volume of tumors. The lowest dose of 5F (12 mg/kg) also decreased the volume of tumors compared with mice received DEN only (Group 4). However, the reduction did not reach a significant point. The in vivo tumorcidal effect of 5F was dose-dependent (Fig. 1a, b).
Potential side-effects of 5F
5F treatment did not significantly affect the body weight of mice (Fig. 1c). It was found that mice treated with 5F had some hair loss compared with mice treated with DEN or saline only, however, this effect was not serious (Table 1). During the whole period of the experiment, no mice showed any sign of intolerance to 5F, decrement of activity, self-isolation, self-torture, and other visible abnormalities.
In order to assess the possible toxic effects of 5F on liver and kidney, we measured 4 biochemical parameters that can reflect the liver and renal functions in vovo. In the liver function test, the levels of AST and ALT were within the normal reference range in all groups tested (Fig. 1d). This indicates that 5F treatment did not result in liver dysfunction in the model tested. In the renal function test, CRE concentrations of all groups were normal (Fig. 1e). The level of BUN was slightly increased in all mice tested (Fig. 1e). It was apparent that the increased value of BUN was still much lower than the panic level [14]. Furthermore, there was not difference between 5F-treated mice and untreated ones, and all mice appeared to be normal during the course of the experiment. Therefore, the results of biochemical parameters tested and physiological observations indicate that 5F treatment did not result in major side-effects.
Inhibitory effect of 5F on the cultured HCC cells
The inhibitory effect of 5F was tested in 5 HCC cell lines, SK-Hep-1, Huh-7, PLC/PRF/5, HepG2, and Hep3B. 5F significantly reduced cell viability in all cell lines tested (Fig. 2a). SK-Hep-1 cells were the most sensitive to 5F whereas Hep3B cells were the least sensitive. The order of the sensitivity to 5F treatment was SK-Hep-1 > Huh-7 > PCL/PFR/5 > HepG2 > Hep3B. It appeared that the inhibitory effect of 5F was dose- and time-dependent.
To determine whether cell death caused was apoptotic, DNA fragmentation of HCC cells treated with 5F was assessed by TUNEL. The result showed that 5F increased DNA fragmentation of PLC/PRF/5 cells in a concentration-dependent manner (Fig. 2b). The similar result was obtained in the other 4 cell lines (data not shown). In situ TUNEL assay also revealed that the TUNEL positive cells were much higher in HCC cells of mice treated with 5F than HCC cells of mice without 5F treatment or liver cells of non-tumor bearing mice treated with 5F or saline (Fig. 2c).
Proliferative and apoptotic molecules changed by 5F
We examined three groups of molecules that are associated with cell proliferation and apoptosis in the DEN-induced HCC mice receiving 5F and cultured HCC cells treated with 5F. The first molecule was PCNA, a cell proliferation marker [19]. The level of PCNA was much higher in HCC liver of DEN-induced mice (Group 4) compared with all other groups (Fig. 3). The reduced expression of PCNA appeared to be dose-dependent in HCC mice treated with 5F. Thus, the finding of PCNA supports the data of cell death and apoptosis in HCC cells treated with 5F (Fig. 2). The second group was Bcl-2 family members: Bcl-2, Bcl-xL, Bax, Bak and Bid. These molecules have been reported to be affected by 5F in other tumor cells [3, 6, 9]. We found that the level of Bcl-2 was increased in HCC liver of DEN-induced mice (Group 4) and 5F treatment significantly decreased its level (Fig. 3). In contrast to Bcl-2, the levels of Bax and Bak were enhanced by 5F treatment (Fig. 3). However, we did not find any difference in the expression of Bcl-xL and Bid between mice treated with 5F and those without 5F treatment (data not shown). The third group tested was nuclear factor kappaB (NF-kB) family, p65, a subunit of NF-kB, and IkBα, an inhibitor of NF-kB [20]. It was found the level of p65 was inhibited by 5F whereas the level of IkBα was up-regulated by 5F (Fig. 3). The changes in both molecules appeared to be in a dose-dependent manner. The alterations of these cell proliferative and apoptotic molecules by 5F in vivo were supported by the result obtained in in vitro cultured HCC cells treated with 5F (Fig. 4a).
The role of NF-kB in 5F-induced cell death was further explored and verified by different approaches. First, 5F prevented the degradation of IkBα induced by TNFα. The level of IkBα was degraded by TNFα in HCC cells in 15–30 min after the treatment, but the degradation was prevented by 5F (Fig. 4b). Second, 5F reduced both basic and TNFα-induced nuclear p65 protein (Fig. 4c), and the effect was confirmed by the decreased activity of NF-kB p65 activity (Fig. 4e). Third, both 5F and Bay 11-7082, a well-known NF-kB inhibitor (21), suppressed Bcl-2 but enhanced Bax and Bak (Fig. 4d), all of which are known-downstream targets of NF-kB (22–24).
Discussion
The current study is the first one to examine the tumorcidal effect as well as the side-effects of 5F in a HCC mouse model induced by diethylnitrosamine (DEN), a well-known chemical and dietary hepatocarcinogen. DEN-induced HCC in animals is one of the best characterized experimental models of HCC [10, 25]. This model closely resembles the major feature of human HCC [11, 26]. Therefore, it has been widely used to investigate hapatocarcinogenesis and screen potential anti-HCC compounds [27–31]. Our result clearly indicated that 5F was able to reduce not only the number of DEN-induced liver tumors but also the total volume of tumors in each individual HCC mouse. This finding is of critical importance since the liver of HCC usually contains multiple foci of malignant lesions and the existence of multiple small foci is the most common factor causing the recurrence of HCC. It was also noted that the higher the dose of 5F, the greater the tumorcidal effect, which further supports the effectiveness of 5F as an anti-HCC agent.
During the last several decades, a number of anti-HCC agents have been proposed and tested. However, most of them have failed to reach the clinical stage mainly due to the unbearable side-effects. Even for those that have passed the clinical trials, their use in HCC patients is also often limited in doses and treatment durations, and such limits are justified not only by the tumor itself but by the side-effects generated [32, 33]. Therefore, it is important to develop effective anti-HCC agents with minimal side-effects. During the entire period of the present in vivo experiment, the food and water intake, body weights as well as physical activity among 8 groups of mice did not differ significantly. It was noted that a mild hair loss was observed in some mice treated with 5F. Fortunately no mice suffered from severe hair loss during or at the end of experiment. These findings indicate that 5F at doses used did not significantly affect the general health of mice. Nevertheless, a further test needs to check whether the hair loss is reversible after ceasing 5F treatment.
The most critical and frequent side-effects generate by anti-tumor agents are the liver and kidney damages. In this study, we demonstrated that while 5F inhibited liver tumor growth, it did not affect liver functions, which were reflected by normal serum levels of AST and ALT, two well-known markers for the liver function [33, 34]. For the renal function, we examined serum CRE and BUN, which represent the general condition of the kidney [34]. It was found that the levels of CRE in all 8 groups of mice tested were within the normal range. However, the levels of BUN in all 8 groups of mice tested were higher than 7.1 mmol/L, the highest value of the normal range [14]. It is noted that there is not difference in the levels of BUN between the control mice that received saline only and those treated with 5F, indicating that the slight increase of BUN in 5F-treated mice was not caused by 5F treatment. Although our experimental data cannot give an explanation for the slight increase of BUN, according to the published information there are two possibilities. First, the normal level of BUN in some mouse species can be as high as around 10–13 mmol/L [35, 36]. If we apply this standard to our C3H/HeJ mice, the level of BUN detected in our model should be within the normal range. Second, increased BUN in the setting of a normal serum CRE may not reflect a pathological condition but a physiological response to a relative decrease of blood flow to the kidney. Thus it does not indicate any true damage to the kidney [37]. Furthermore, compared with BUN, serum CRE is a more specific indicator of the renal function [34, 37]. Therefore, the result of BUN does not appear to draw a conclusion that 5F would result in a significant injury to the kidney. Together, our results demonstrate that 5F is not toxic to liver and kidney in the model tested.
Induction of tumor cell death by apoptosis is a major mechanism employed by chemotherapeutic agents and this may be particularly relevant to HCC since the onset of HCC is the result of the imbalance between proliferation and apoptosis in hepatocytes [2]. In the present study, apoptosis in liver tumor cells of 5F-treated mice was determined by the classic TUNEL method and its level was much higher in 5F-treated mice than the mice without 5F treatment. The promotive effect of 5F on apoptosis was further evident by in vitro cultured experiments, in which 5F induced apoptosis of HCC cells in a dose-dependent manner. The increase of apoptosis in tumor cells by 5F was in line with the results of decreased PCNA staining and reduced viability of tumor cells. Therefore, the tumorcidal effect of 5F is mainly via the induction of apoptosis.
In order to elucidate the molecular mechanism involved in 5F-mediated induction of apoptosis, we examined the effect of 5F on the expression of NF-kB and Bcl-2 family members. In HCC, NF-kB is constitutively activated and functions as a survival factor in the tumor development [38, 39]. We found that 5F was able to stabilize the NF-kB inhibitor cellular IkBα and prevent it from degradation. The degradation of IkBα is a critical step of NF-kB activation [20]. The failure of IkBα degradation inhibits the NF-kB subunits to translocate to the nucleus, reducing the level/activity of nuclear NF-kB, which is evident in our current study showing the decreased nuclear p65 level and the reduced NF-kB activity. A number of anti- and pro-apoptotic molecules is controlled by NF-kB. Among them are Bcl-2, Bax and Bak. NF-kB can upregulate the anti-apoptotic Bcl-2 by binding to the Bcl-2 promoter whereas it downregulate pro-apoptotic Bax by recruiting repressor complexes to Bak promoter [22, 23]. NF-kB can also inhibit the expression of Bak by promoting Bfl-1, a Bak antagonist [24]. Therefore, these established mechanisms can well explain the decreased level of Bcl-2 but increased levels of Bax and Bak seen in HCC cells treated with 5F. The roles of NF-kB in the regulation of Bcl-2, Bax and Bak in HCC cells are further verified using a well-known NF-kB inhibitor Bay 11-7082 [21]. Block of NF-kB pathway by Bay 11-7082 leads to reducing Bcl-2 but increasing Bax and Bak in a manner similar to the administration of 5F. The alteration of Bcl-2, Bax and Bak by 5F should be deemed to be significant not only by their roles in the regulation of apoptosis but also the pathological change of these molecules in HCC. The increased level of Bcl-2 and the decreased level of Bax and Bak are known to contribute to the hepatocarcinogenesis or enable HCC cells resistant to anti-tumor treatments [40–45].
In conclusion, 5F is effective against HCC with minimal side effects. It induces apoptosis in HCC cells via stabilizing NF-kB inhibitor IkBα, resulting in the decrease of anti-apoptotic Bcl-2 and increase of pro-apoptotic Bax and Bak.
References
Lencioni R, Chen XP, Dagher L, Venook AP (2010) Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15(Suppl 4):42–52
Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989–5005
Lan L-B, Linag N-C, Mo L-E, Deng Y-F (2003) Purification of 5F from Pteris semipinnata and its enhanced cytotoxicity in vitro. Chinese Pharmacological Bulletin 19:804–807
Chen GG, Linag NC, Lee JF, Chan UP, Wang SH, Leung BC et al (2004) Over-expression of Bcl-2 against Pteris semipinnata L-induced apoptosis of human colon cancer cells via a NF-kappa B-related pathway. Apoptosis 9:619–627
He T-P, Mo L-E, Linag N (2005) Effects of 5F from Pteris semipinnata L on expression of NF-kB and FAK protein in HO-8910PM cells. Chin J Cancer Prev Therat 12:565–568
Liu Z, Ng EK, Linag N, Deng YF, Leung BC, Chen GG (2005) Cell death induced by Pteris semipinnata L. is associated with p53 and oxidant stress in gastric cancer cells. FEBS Letters 579:1477–1487
Liu ZM, Chen GG, Vlantis AC, Liang NC, Deng YF, van Hasselt CA (2005) Cell death induced by ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid in anaplastic thyroid carcinoma cells is via a mitochondrial-mediated pathway. Apoptosis 10:1345–1356
Li MY, Leung J, Kong AW, Liang NC, Wu K, Hsin MK et al (2010) Anticancer efficacy of 5F in NNK-induced lung cancer development of A/J mice and human lung cancer cells. J Mol Med 88:1265–1276
Vlantis AC, Lo CS, Chen GG, Liang CN, Lui VW, Wu K et al (2010) Induction of laryngeal cancer cell death by Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid. Head Neck 32:1506–1518
Lee GH, Nomura K, Kanda H, Kusakabe M, Yoshiki A, Sakakura T et al (1991) Strain specific sensitivity to diethylnitrosamine-induced carcinogenesis is maintained in hepatocytes of C3H/HeN in equilibrium with C57BL/6N chimeric mice. Cancer Res 51:3257–3260
Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J et al (2008) Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 47:2078–2088
Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105:20–23
Gee MS, Koch CJ, Evans SM, Jenkins WT, Pletcher CH Jr, Moore JS et al (1999) Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 59:4882–4889
Jacobs DS, Oxley DK, DeMott WR (2002) Laboratory test handbook, 2nd edn. Lexi-Comp, Hudson
Chen GG, Lai PBS, Chak ECW, Lau WY (2001) Immunohistochemical analysis of pro-apoptotic Bid level in chronic hepatitis, hepatocellular carcinoma and liver metastases. Cancer Lett 172:75–82
Chen GG, Chan UPF, Bai L, Fung KY, Tessier A, To AKY et al (2009) ZBP-89 reduces the cell death threshold by increasing caspase-6 and S phase arrest in hepatocellular carcinoma. Cancer Letters 283:52–58
Miao J, Chen GG, Chun SY, Yun JP, Chak ECW, Ho RLK et al (2006) Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma. International Journal of Cancer 119:1985–1993
Gramantieri L, Trerè D, Chieco P, Lacchini M, Giovannini C, Piscaglia F et al (2003) In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. J Hepatol 39:997–1003
Loeppky RN (1999) The mechanism of bioactivation of N-nitrosodiethanolamine. Drug Metab Rev 31:175–193
Van Waes C (2007) Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13:1076–1082
Ghashghaeinia M, Toulany M, Saki M, Bobbala D, Fehrenbacher B, Rupec R et al (2011) The NFĸB pathway inhibitors Bay 11-7082 and parthenolide induce programmed cell death in anucleated Erythrocytes. Cell Physiol Biochem 27:45–54
Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ (2005) Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56:46–54
Cianfrocca R, Muscolini M, Marzano V, Annibaldi A, Marinari B, Levrero M et al (2008) RelA/NF-kappaB recruitment on the Bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ 15:354–363
Simmons MJ, Fan G, Zong WX, Degenhardt K, White E, Gélinas C (2008) Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist. Oncogene 27:1421–1428
Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK et al (2010) Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2: 32ra35
Bishayee A, Mbimba T, Thoppil RJ, Háznagy-Radnai E, Sipos P, Darvesh AS et al (2011) Anthocyanin-rich black currant (Ribes nigrum L.) extract affords chemoprevention against diethylnitrosamine-induced hepatocellular carcinogenesis in rats. J Nutr Biochem 2011 (In press)
Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121–124
García A, Zeng Y, Muthupalani S, Ge Z, Potter A, Mobley MW et al (2011) Helicobacter hepaticus–induced liver tumor promotion is associated with increased serum bile acid and a persistent microbial-induced immune response. Cancer Res 71:2529–2540
Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S et al (2011) In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 54:252–261
Amin A, Hamza AA, Bajbouj K, Ashraf SS, Daoud S (2011) Saffron: A potential candidate for a novel anticancer drug against hepatocellular carcinoma. Hepatology 54:857–867
Khan MS, Devaraj H, Devaraj N (2011) Chrysin abrogates early hepatocarcinogenesis and induces apoptosis in N-nitrosodiethylamine-induced preneoplastic nodules in rats. Toxicol Appl Pharmacol 251:85–94
Ramadori G, Cameron S (2010) Effects of systemic chemotherapy on the liver. Ann Hepatol 9:133–143
Gracias VH, McGonigal MD (2000) Monitoring organ function. Heart, liver, and kidney. Surg Clin North Am 80:911–919, x
Yao Y, Chen F, Wang M, Wang J, Ren G (2008) Antidiabetic activity of Mung bean extracts in diabetic KK-Ay mice. J Agric Food Chem 56:8869–8873
de Vries B, Köhl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P et al (2003) Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 170:3883–3889
Goldenberg I, Moss AJ, McNitt S, Barsheshet A, Gray D, Andrews ML et al (2010) Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm 7:1777–1782
Chiu CT, Yeh TS, Hsu JC, Chen MF (2003) Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci 48:670–676
Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP et al (2006) Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Human Gene Therapy 17:280–290
Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T et al (2009) Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol 76:957–968
Pizem J, Marolt VF, Luzar B, Cör A (2001) Proliferative and apoptotic activity in hepatocellular carcinoma and surrounding non-neoplastic liver tissue. Pflugers Arch 442:R174–176
Luo D, Cheng SC, Xie H, Xie Y (1999) Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol 20:331–340
Guo XZ, Shao XD, Liu MP, Xu JH, Ren LN, Zhao JJ et al (2002) Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol 8:1059–1062
Liu LX, Jiang HC, Liu ZH, Zhu AL, Zhou J, Zhang WH et al (2003) Gene expression profiles of hepatoma cell line BEL-7402. Hepatogastroenterology 50:1496–1501
Rousseau B, Menard L, Haurie V, Taras D, Blanc JF, Moreau-Gaudry F et al (2007) Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology 46:1108–1118
To AK, Chen GG, Chan UP, Ye C, Yun JP, Ho RL et al (2011) ZBP-89 enhances Bak expression and causes apoptosis in hepatocellular carcinoma cells. Biochim Biophys Acta 1813:222–230
Acknowledgements
This study was supported by a grant from Innovation and Technology Fund of Innovation and Technology Commission, the government of the Hong Kong Special Administration Region, Project No: GHP/022/06.
Conflict of Interest
All authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, G.G., Leung, J., Liang, N.C. et al. Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα. Invest New Drugs 30, 2210–2218 (2012). https://doi.org/10.1007/s10637-011-9791-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-011-9791-5